Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib

Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Englinger, Bernhard, Laemmerer, Anna, Moser, Patrick, Kallus, Sebastian, Röhrl, Clemens, Pirker, Christine, Baier, Dina, Mohr, Thomas, Niederstaetter, Laura, Meier‐Menches, Samuel M., Gerner, Christopher, Gabler, Lisa, Gojo, Johannes, Timelthaler, Gerald, Senkiv, Julia, Jäger, Walter, Kowol, Christian R., Heffeter, Petra, Berger, Walter
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://ncbi.nlm.nih.gov/pubmed/32064608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32924
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados